Lightchain Capital

Recent News

C4-logo-wht
March 05, 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

READ MORE
C4-logo-wht
March 04, 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

READ MORE
C4-logo-wht
February 22, 2024

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

READ MORE
wugen-logo-400
January 30, 2024

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

READ MORE
aiProteins_Final_logo300
January 18, 2024

Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases

READ MORE
Logo-Geneoscopy-400
January 17, 2024

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

READ MORE
Logo-Geneoscopy-400
January 12, 2024

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

READ MORE
C4-logo-wht
January 09, 2024

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

READ MORE
C4-logo-wht
January 04, 2024

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group